Journal Article10.1016/J.SCHRES.2004.12.018
Strategies to increase central N-acetyl aspartylglutamate: a potential treatment for schizophrenia and bipolar disorders.
2
About: This article is published in Schizophrenia Research. The article was published on 15 Jul 2005. The article focuses on the topics: Schizophrenia.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
Stefan Golz,Ulf Brueggemeier,Andreas Geerts +2 more
- 21 Jul 2005
TL;DR: In this paper, a human PSMAL which is associated with the cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, gastroenterology diseases, inflammation, hematological disease, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases.
2
Patent
Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal)
Stefan Golz,Ulf Brüggemeier,Andreas Geerts +2 more
- 21 Jul 2005
TL;DR: L'invention concerne une proteine similaire a un antigene membranaire specifique de the prostate (PSMAL) humaine associee aux maladies cardio-vasculaires, au cancer, auxmaladies endocriniennes, aux mal Ladies gastroenterologiques, aux inflammations, de maladies hematologiques
References
NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR
Rafal T. Olszewski,Rafal T. Olszewski,Noreen Bukhari,Jia Zhou,Alan P. Kozikowski,Alan P. Kozikowski,Jarda T. Wroblewski,Susan Shamimi-Noori,Barbara Wroblewska,Tomasz Bzdega,Stefano Vicini,Franca B. Barton,Joseph H. Neale +12 more
TL;DR: The view that NAAG peptidase inhibitors may represent a new therapeutic approach to some of the components of schizophrenia that are modeled by PCP is supported.
155
A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients.
TL;DR: The possibility that Magnesiocard could replace or improve the efficacy of lithium as a preventive treatment of manic-depressive illness merits further clinical investigation.
65
Proton magnetic resonance spectroscopy of the human brain in schizophrenia.
TL;DR: There are no consistently replicated findings for choline or creatine alterations in any of the brain regions examined in schizophrenia, and significant technical difficulties make reliable measurement of glutamine and glutamate problematic at the present time.
47
•Journal Article
Transport of N-Acetylaspartate by the Na+-Dependent High-Affinity Dicarboxylate Transporter NaDC3 and Its Relevance to the Expression of the Transporter in the Brain
Wei Huang,Haiping Wang,Ramesh Kekuda,You Jun Fei,Anne Friedrich,Jian Wang,Simon J. Conway,Richard S. Cameron,Frederick H. Leibach,Vadivel Ganapathy +9 more
TL;DR: The ability of NaDC3, a Na(+)-coupled high-affinity dicarboxylate transporter, to transport N-acetylaspartate is investigated and it is established that this transporter is likely to be an essential component in the metabolic role of N- acetyl aspartate in the process of myelination.
Primary Structure and Functional Characteristics of a Mammalian Sodium-coupled High Affinity Dicarboxylate Transporter
Ramesh Kekuda,Haiping Wang,Wei Huang,Ana M. Pajor,Frederick H. Leibach,Lawrence D. Devoe,Puttur D. Prasad,Vadivel Ganapathy +7 more
TL;DR: Data show that NaDC3 interacts preferentially with the divalent anionic species of citrate, and this represents the first report on the cloning and functional characterization of a mammalian Na+-dependent, high affinity dicarboxylate transporter.